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Interleukin  1 (IL-1), l a  polypeptide hormone produced by activated macro- 
phages, has been reported to mediate an apparently diverse range of biological 
activities (1-3).  These include lymphocyte-activating factor (LAF) (4),  endoge- 
nous  or  leukocyte pyrogenic activity (5),  epidermal  cell  thymocyte-activating 
factor (6),  bone  resorption  factor (7,  8),  and  fibroblast growth factor (9).  In 
general, this set of activities would seem to be consistent with the notion that IL- 
l  acts as a  soluble mediator during inflammatory responses. We have recently 
purified to homogeneity a polypeptide secreted by human monocytes that pro- 
duces several IL-l-like effects (10). 
The initial step in the action of IL-1 is most likely the binding of this hormone 
to plasma membrane receptors. The availability of purified IL-1 in our laboratory 
rendered a search for such receptors possible. For the initial characterization of 
the plasma membrane (IL-1) receptors, we chose the murine T lymphoma LBRM- 
33-1A5  as  a  model cell.  This  cell  line produces  interleukin  2  in  response  to 
suboptimal doses of phytohemagglutinin (PHA) in an IL-l-dependent fashion, 
and constitutes a well-defined model system for IL-1 action (11,  12). 
Using radiolabeled human IL-1, we show that these cells bind IL-1 specifically 
and with high affinity. We further show that cell-bound IL-1 is associated with a 
membrane protein of -80,000 mol wt. Finally, we have surveyed a broad range 
of cell types from several species for 125I-IL-1 binding. In general, the data are 
consistent with the known biological effects of IL-1, in that cell types which bind 
IL-1 are those previously reported to respond to it. The cell types that showed 
significant levels of IL-1  binding were either lymphoid in origin or fibroblast/ 
epithelial  type  cells.  The  data  support  the  view  that,  like  other  polypeptide 
hormones,  IL-1  action  is  mediated  by  a  specific  plasma  membrane  receptor 
protein. The characterization of this protein, both at the functional and structural 
levels, should aid in understanding the diverse biological activities of IL-1. 
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z Abbreviations used in this paper:  BSA,  bovine serum albumin; DSP, dithiobis-succinimidyl  pro- 
pionate; DSS, disuccinimidyl  suberate; DST, disuccinimidyl  tartrate; IL-I, IL-2, interleukins 1 and 
2; PBS, phosphate-buffered  saline; PHA, phytohemagglutinin;  PMSF, phenylmethylsulfonyl  fluoride; 
SDS-PAGE, sodium dodecyl  sulfate-polyacrylamide  gel electrophoresis. 
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MateriaLs  and  Methods 
Cell Preparations.  Cell lines were propagated in  175-cm ~ tissue culture flasks at 37°C 
in 5% CO2, in RPMI 1640 containing 10% fetal calf serum. Cell lines that grow adherently 
were harvested by scraping without prior trypsin treatment  to avoid the possibility that 
IL-1 receptors would be lost due to proteolytic degradation.  In some cases a brief EDTA 
treatment was used to aid in detachment. 
Murine  thymocytes,  splenocytes,  and  lymph  node  cells  were  isolated  as  single-cell 
suspensions from tissues.  Fractionation of thymocytes by peanut lectin (Arachius hypogeae) 
was done by agglutination (13), followed by separation on fetal bovine serum (14). Human 
peripheral  blood mononuclear cells were isolated from whole human blood by standard 
procedures (15). 
Hormone  Preparations.  Thyroid-stimulating  hormone  (TSH),  luteinizing  hormone 
(LH),  human  growth  hormone  (GH),  bovine  insulin,  and  follicle-stimulating  hormone 
(FSH) were purchased  from Calbiochem-Behring Corp.  (La Jolla,  CA).  Platelet-derived 
growth factor (PDGF), epidermal  growth factor (EGF), nerve growth factor (NGF), and 
fibroblast growth factor (FGF),  were purchased  from Bethesda  Research  Laboratories, 
(Gaitbersburg,  MD).  Human  recombinant  IL-2 was expressed  in, and purified  from, E. 
coil and was provided under a collaboration between  Hoffmann-La Roche, Inc. (Nutley, 
N  J) and  Immunex Corporation.  Colony-stimulating factor 2a (CSF-2a)  was purified  as 
described previously (16). 
Purification  and Radiolabeling  of Human IL-1.  IL-1 was isolated from supernatants of 
human mononuclear cells cocultured with heat-killed, formalin-fixed Staphylococcus aureus 
for 24 h at 37°C. Purification of IL-1 was done by using sequential SP-Sephadex, DEAE- 
Sephacel, and Procion red agarose column chromatography as described elsewhere (10). 
This material has a specific activity of~5 x  10 l° (U/rag) in the LBRM-33-1A5 conversion 
assay and contains a single 17,500 mol wt protein by sodium dodecyl sulphate-polyacryl- 
amide gel electrophoresis (SDS-PAGE) analysis. Before radioiodination, IL-1 was concen- 
trated to ~ 10 ug/ml by rechromatography on a 0.5 ml bed volume SP-Sephadex column, 
and eluted with 0.02 M sodium borate, 0.15 M sodium chloride, pH 8.5. The concentra- 
tion of the final solution was estimated by silver staining (17) of an aliquot run on SDS- 
PAGE. 
Purified  IL-1  was  labeled  using  diiodo(125I)-Bolton-Hunter  reagent  (New  England 
Nuclear,  Boston,  MA) according to the manufacturer's instructions.  Briefly, 200  ng of 
IL-1 in 20 tsl of SP-Sephadex elution buffer was mixed with 5 #1 of 0.1  M sodium borate, 
0.75  M  NaCI, pH 8.5 and added to a vial in which  100 #1 of benzene containing 1 mCi 
(0.23 nmol) of Bolton-Hunter reagent had been evaporated using a gentle stream of dry 
nitrogen.  The reaction  was allowed  to proceed  for  1 h  on  ice and  was terminated  by 
addition  of 5 ul  of 1 M  glycine ethyl ester.  30 #1 of 2%  gelatin in phosphate  (0.05  M)- 
buffered  saline  (0.15  M) pH  7.4  (PBS),  was added  as a  carrier,  and  labeled  IL-1  was 
separated  from free Bolton-Hunter reagent  by chromatography on a  1 ml bed volume 
column of Biogel P6 (Bio-Rad Laboratories, Richmond, CA) packed in a pasteur pipette. 
The column bed material was blocked with BSA and subsequently washed with 20 ml of 
PBS to remove unbound bovine serum albumin (BSA) before use.  100-#1 fractions were 
collected and fractions containing protein-bound  radioactivity were pooled.  Due to the 
small amounts of IL-1 available to us, direct estimates of the recovery after the radiola- 
beling were not possible. To estimate recovery, control experiments were done in which 
125  4  IL-1  (200  rig)  was mixed  with  '  I-IL-1 (3  x  10  cpm) and put  through  the  iodination 
procedure, with the omission of Bolton-Hunter reagent. In five replicate experiments,  54 
_+ 8% of the counts were recovered after the gel filtration step. In subsequent iodinations, 
this percentage was taken as the recovery of IL-1 protein. Using this estimate, the specific 
activity of the  radiolabeled  IL-1  preparations  was  2-5  X  1015 cpm/mmol,  based  on  a 
molecular weight of 17,500. 
Assay oflL-1 Biological Activity.  IL-1 biological activity was monitored using the IL-1 
conversion assay as described by Conlon (12). This assay depends on the fact that, in the 
presence of 0.1%  PHA, the  LBRM-33-1A5 cell line produces IL-2 only in the presence 
of exogenous  IL-I. The resulting  IL-2 produced is assayed,  in turn,  by the capacity to DOWER  ET  AL.  503 
maintain proliferation of the murine T  cell line CTLL-2. The proliferation of the CTLL- 
2 cells, measured by [3H]thymidine incorporation, is hence dependent on the concentra- 
tion of IL-1  in which the LBRM-33-1A5 cells are initially incubated.  A  solution of IL-1 
containing 1 U/ml produces 50% of maximal incorporation of [3H]thymidine in the assay. 
Binding Assays.  Cells and  ~ZSl-lL-1 were incubated  in binding medium (RPMI  1640 
containing 1% BSA, 0. 1% sodium azide, and 20 mM Hepes, pH 7.2)at a concentration 
of 6.7 ×  107 cells/ml and the appropriate concentration of ~25I-IL-1, in a total volume of 
150  #1,  for  a  time  estimated  to  allow  the  system  to  reach  equilibrium  (see  below). 
Incubations were carried out at 8 °C, on a rocker platform, to ensure continuous mixing 
of cells and radioactive ligand. Nonspecific binding of ~25I-IL-1 was measured by incuba- 
tions in  the  presence of at  least  a  20-fold molar excess of unlabeled  IL-1, at a  dose of 
unlabeled ligand predetermined  to lead to  100% receptor occupancy. At the end of the 
incubation, bound and free ~251-1L-1 were separated by removing duplicate 60-#1 aliquots 
from the incubation mixture, layering these on 200 #1 of a phthalate oil mixture in 400- 
~1 polyethylene centrifuge tubes (VWR Scientific Div.,  Univar, San  Francisco,  CA) and 
centrifuging for 30 s in a microfuge. The oil mixture,  1.5 parts dibutyi phthalate,  1 part 
bis(-2-ethylhexyl)-phthalate (Eastman Kodak Co., Rochester, NY), allows cells to sediment 
but is more dense than binding medium. Bound and free ligand were estimated by cutting 
the tube  in  half and counting the  top and tip as described previously (18,  21).  Human 
gingival fibroblasts (a kind gift of Dr. R. C. Page, University of Washington), were assayed 
for IL-1 receptors in situ in 24-well Linbro plates after at least 48 h of postpassage culture. 
For association  kinetics experiments,  incubation  mixtures containing either  ~25I-IL-1 
alone or l'~SI-IL-1 and excess unlabeled IL-1 were prepared.  At the start of the reaction, 
cells were added.  At various subsequent  times,  duplicate  60-tA  aliquots of the  mixture 
were removed; bound and free lzsI-IL-I were separated by the phthalate  oil method as 
described above. The time of measurement was taken as time of initiation of centrifuga- 
tion.  For dissociation kinetics, cells were incubated in the presence of 150 ~1 of binding 
medium containing 125I-IL-1  for 4  h. Cells were then sedimented  in two separate  75-gl 
aliquots  and  resuspended  in  either  1  ml  binding  medium  or  1  ml  binding  medium 
1  containing 5 X  10-  M unlabeled IL-1. The t'me at which the cells were resuspended was 
taken  as  the  start  of the  reaction.  Samples were  taken  at  various subsequent  times,  as 
described  for  the  association  kinetics  experiments.  In  general,  cell-bound  counts  per 
minute in these experiments were 100-5,000; therefore, all samples were counted for 10 
rain or longer. 
Affinity  Crosslinking and SDS-PAGE.  Crosslinkers  disuccinimidy[  suberate  (DSS),  di- 
thiobis-succinimidyl propionate (DSP), and disuccinimidyl tartrate (DST) were purchased 
from the Pierce Chemical Co. (Rockville, IL). For crosslinking,  10 7 cells were incubated 
with  5  x  10 -j°  M  ~25I-IL-1  in  150  tA  of binding  medium  alone  or  binding  medium 
containing 8 x  10 -s M unlabeled IL-1 for 2 h at 8°C. Subsequently, the cells were washed 
twice by centrifugation  with  1 ml PBS, pH 7.4 and resuspended  in  100 ~1 PBS.  2 ul of 
crosslinker (50 mg/ml) in dimethyl sulphoxide were added to give a final concentration 
of I  mg/ml, and the mixture was incubated for 1 h at 8°C. The ceils were then washed 
twice with PBS and finally resuspended in 50 gl PBS containing 1% Triton X-100 and 2 
mM  phenylmethylsulphonyl  fluoride  (PMSF).  The  detergent  extraction  mixture  was 
incubated  for 5  min on ice and  then  centrifuged for  15 min at  8°C in a  microfuge to 
remove nuclei and other cell debris.  I0 t~l of the supernatant  was removed for gamma 
counting and 40 ~1 was removed and frozen at -20°C until SDS-PAGE analysis. To each 
of these samples 2 ~1 of 10%  SDS was added and the sample dried  under vacuum. The 
dried aliquots were resuspended in 60 ul of sample buffer (0.06 M Tris-HCl, pH 6.8, 2% 
SDS,  10%  glycerol) in the  presence  or absence  of 5%  2-mercaptoethanol,  boiled  for 3 
rain,  and  then  subjected  to  electrophoresis  in  8%  PAGE  gels  using  the  stacking  gel 
procedure of Laemmli (19) as described elsewhere (20). 
Control experiments were performed in which the time of incubation with crosslinker 
and  the  concentration  of crosslinker  used  were varied.  Further,  a  mixture  of protease 
inhibitors (pepstatin,  2 mM final [Sigma Chemical Co., St. Louis, MO], 0-phenanthroline, 
2  mM  final,  and  PMSF,  2  mM  final)  was  used  in  some experiments  in  an  attempt  to 504  CELL  SURFACE INTERLEUK1N  1 RECEPTORS 
prevent proteolytic degradation of the ~25I-IL-1/IL-1  receptor complex after extraction 
from the cells. 
Data Analysis.  Curve fitting of binding and kinetic data was done using RS/1  (BBN 
Software Products Corporation, Cambridge, MA), a commercially available scientific data 
processing package running on a VAX 11/750 under the VMS operating system. Kinetic 
data  were  analyzed  with  functions  that  are  sums  of exponential  terms  as  described 
elsewhere (21,  27);  binding data  were analyzed with sums  of simple  Michaelis-Menten 
terms as described (22); and inhibition data were analyzed with an equation for competitive 
inhibition between two ligands for one type of site (23). 
Results 
Radiolabeling  of Human  IL-1.  Fig.  1  shows  SDS-PAGE analysis  of the  125I- 
Bolton-Hunter  reagent-labeled  IL-!  preparation  used  in  the  binding  studies. 
The radiolabeled protein  in  the preparation  migrated with an Mr of ~17,500, 
characteristic of IL-t. The specific biological activity of this material  was only 
5% of the activity (biological units per milligram protein) of the material before 
radiolabeling. However, comparison of the binding of radiolabeled 12"5I-1L-  1 with 
that of unlabeled IL-1  measured by inhibition revealed little, if any, decrease in 
binding activity for LBRM-33-1A5 cells (see below). 
Several tyrosine-directed methods  of iodination  were  tried,  including chlor- 
amine  T  (24),  iodogen  (25),  and  lactoperoxidase  (26).  Of these,  only the  last 
gave a product with any detectable binding activity, and this was at least  10-fold 
lower  in  affinity  than  unmodified  IL-1.  Finally,  the  source  of our  material, 
stimulated  peripheral  blood  mononuclear  cells,  renders  biosynthetic  labeling 
with,  for example, [3"~S]methionine, impractical.  We therefore chose to use the 
Bolton-Hunter method for further studies. 
Interaction of  lL-I with Plasma Membrane Receptors on LBRM-33-1A5 Cells.  Fig. 
2 shows the association kinetics of 12~I-IL-1  with LBRM-33-1A5 cells at 8°C; all 
data are corrected for nonspecific binding.  The data in  Fig.  2A show that both 
FIGURE  1.  SDS-PAGE  of 12~I-labeled IL-1. l~51-1abeled IL-1 (33,000 cpm) was boiled for 3 
rain in sample buffer containing 5% 2-mercaptoethanol, and subjected to electrophoresis on a 
! 0-20% polyacrylamide gradient according to the stacking gel procedure of Laemmli (! 9). 
The position of various molecular weight markers (Sigma Chemical Co., St. Louis, MO) is 
indicated at left. 80 
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FIGUR~ 2.  Association kinetics of 1251-1L-1 with LBRM-33-1A5 cells at 8°C. (A) LBRM-33- 
1A5 cells (5.3 X 107 cells/ml) were incubated with (A) 3.62 x  10  -1° M, (O) 1.16 x  10  -l° M, or 
(r-I) 3.54  x  10  -u  M  I~sI-IL-I  for various  periods.  Nonspecific  binding,  measured  in  the 
presence of 6 x  10  -° M unlabeled  IL-I, was 1.15 x  10 u molecules/(celI-M).  The continuous 
curves passing through the data were calculated  from the best-fit parameter values using a 
single exponential  term. Infinite time binding:  (A) 82.4 +  3.4 molecules/cell,  (O) 37.5 +  2.0 
molecules/cell,  (D)  14.6 4- 0.9 molecules/cell;  association rate constants:  (A) 1.25 4- 0.21  x 
10-'/(M .min); (O) 0.49 4- 0.08 ×  10-'/(M.min); (D) 0.35 4- 0.05 x  10-1/(M .min). (B) Plot of 
the value of the association rate constant against the molar concentration of ]esI-IL-1 initially 
present in the medium. 
the  final  equilibrium  amount  bound  to  the  cells  and  the  rate  of approach  to 
equilibrium  are dependent  on the concentration  of ~25I-IL-1 initially present  in 
the medium.  The  curves passing through  the data  in Fig.  2A are best-fit single 
exponential  time  dependency  curves,  consistent  with  the  presence  of a  single 
population of receptors on the cells. Fig, 2 B shows the dependence of the pseudo 
first-order  forward  rate  constant  (determined  by curve fitting  the  data  of Fig. 
2A) on  the  concentration  of ]25I-IL-1  in  the  medium.  As  described  elsewhere 
(27),  for a  bimolecular  reaction,  such  data  should  fit  a  straight  line,  the  slope 
being  the  forward  rate  constant  and  the  intercept  on  the  ordinate  being  the 
reverse rate constant.  The  data  in Fig.  2B do indeed fall on a  straight  line,  and 
the  parameter  values  were  2.8  (+0.3)  x  108/(M-min)  for  the  forward  rate 
constant and  2.1  (+0.6)  X  10-2/min  for the reverse rate  constant.  The  ratio  of 
these numbers gives a range of values for the affinity constant of the radiolabeled 
IL-1 preparation  for its receptor of 0.9-2.0  X  10]°/M.  These affinity values are 
on the high end of the range we have found for 125I-IL-l. Probable  reasons  for 
fluctuations in the values of Ka are discussed below. 
A  striking feature  of the data in Fig.  2A is the low number  of IL-1 molecules 
bound  to the  cells  at  equilibrium.  Since  the  affinity of IL-1  is  high,  relative  to 
the  concentrations  of ligand  used  in  the  experiment,  this  does  not reflect  low 
fractional site occupancy but a  low level of receptor expression.  Such low levels 
of receptor  expression  have  been  a  consistent  finding  in  these  studies.  Finally, 506  CELL  SURFACE  INTERLEUKIN  1  RECEPTORS 
the information  obtained from the experiment  illustrated  in Fig.  2 was used to 
ensure  that,  in  all  subsequent  binding  experiments,  the  system  had  reached 
equilibrium. 
Fig.  3  shows the  dissociation  of ]25I-IL-1  from  LBRM-33-1A5  cells at  8°C. 
The  experimental  design  followed that  originally  described by Demeyts et al. 
(28), and was constructed to test whether the IL-1  receptor exhibits any coop- 
erative properties. A comparison of the dissociation of 125I-IL-1 from the cells in 
medium alone, when only a  fraction (~20-50%) of the receptors are occupied, 
with  that  in  the  presence  of 5  x  l0 -9  M  unlabeled  IL-1,  when  almost all  the 
receptors  are  occupied,  reveals  that  the  rate  of dissociation  of IL-1  from  its 
receptor is insensitive to occupancy of adjacent receptors. This suggests that IL- 
l  receptors on  LBRM-33-1A5 cells are  noncooperative.  The  dissociation  rate 
constants measured in this experiment were 2.2 (+0.8) X  ]0-2/rain  in medium 
alone and 2.6 (_+ 1.1) x  10-2/rain in the presence of unlabeled IL- 1. These values 
are averages, since neither curve is a  simple first-order process. Complex disso- 
ciation kinetics appear to be generally observed for cell surface receptor systems 
(22,  27-30).  The  cause(s)  for such  complex  kinetics  remain  unclear,  but  the 
complexity does not necessarily result from site heterogeneity.  Finally, the data 
in Fig. 3 show that, during procedures such as affinity crosslinking,  it is possible 
to subject LBRM-33-1A5 cells bound to 125I-IL-1 to repeated washes and retain 
a significant fraction of the IL-1 bound to the cell surface. 
Fig. 4 shows the binding of I25I-IL-1  to LBRM-33-1A5 cells at 8°C. The data 
confirm  the results of the association kinetics experiments  (Fig.  2),  in that  the 
level  of receptor  expression  is  low.  The  background  binding,  shown  by  the 
dashed  line  (Fig.  4),  is a  significant  fraction  of the  total.  Plotting  the  specific 
binding data (total -  background) in the Scatchard coordinate system (Fig. 4B) 
revealed a  slight curvilinearity at high  concentrations.  We therefore attempted 
to  analyze  the  data  using  a  model  containing  two  classes  of sites  on  the  cell 
surface (22). The analysis showed that the high affinity sites were present at 290 
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FIGURE  3.  DissociationoflL-lfromLBRM-33-1A5cellsat8°C. 8 x107 cells were incubated 
with  ]~sI-IL-1  for  4  h  at  8°C  in  150  ~l  of binding  medium.  The  ceils  were  pelleted  and 
resuspended in  medium  (A)  or  in  medium  containing  5  ×  10 -9  M  unlabeled  IL-1  (O),  as 
described in Materials and Methods. The cells bad 280 molecules IL-1 bound per cell at time 
zero. Free l~51-1L-1 concentration during the dissociation incubation was 5,3 X  10 -1] M. DOWER  ET  AL.  507 
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FIGURE  4.  Binding of 1251-IL-1 to LBRM-33-1A5 cells at 8°C.  LBRM-33-1A5 cells (6.7  × 
107 cells/ml) were incubated with '~sI-IL-1 for 4  h  at 8°C. Nonspecific binding, measured in 
the presence of 1.57 ×  10 -7 M unlabeled IL-1, was 122 molecules/cell at 9  x  10 -~° M  '~I-IL- 
1, and 30 molecules/cell at 2.95 ×  10  -1° M, giving an average value of 1.20 ×  1011 molecules/ 
(cell- M). (a) Data plotted as bound (r) vs. free (c) '~sI-IL-I: (A) total binding, (- - -) nonspecific 
binding. (O) specific binding (total -  nonspecific). (B) Specific binding from A replotted in the 
Scatcbard coordinate system. The continuous curves in both panels were calculated from the 
best-fit binding  parameters  given  in  the  text.  Curve  fitting  was  done  as  described  in  the 
Materials and Methods. 
+_. 70  sites per cell, and that they bound IL-1  with an affinity of 1.96 (+0.8) X 
10~/M.  The  low-affinity binding was too weak  for complete analysis, but  the 
product of the site number and affinity was 8.7  (+1.5)  x  10 '° molecules/(cell. 
M). The curves passing through the specific binding data in both panels of Fig. 
4 are calculated from these values. In other experiments the low-affinity binding 
could not be detected and, when present, may reflect an error in estimating the 
background rather than a  true low-affinity receptor population. In a  series of 
binding experiments with LBRM-33-1A5 cells at 8°C, we found that the level 
of high affinity IL-1 receptor expression fluctuated considerably; the results are 
summarized  in  Table  I.  In  a  similar  experiment  carried  out  at  37°C,  the 
parameters estimated were 266 -+ 50 sites per cell and a ~25I-IL-1 binding affinity 
of 1.8 (+0.5) x  109/M. Considering experimental error, the parameters for the 
high affinity binding were the same at 37°C as at 8°C. 
Fig.  5 shows the inhibition of binding of '25I-IL-1  to LBRM-33-1A5 cells  at 
8°C  by unlabeled IL-1.  The experiment was done to determine whether the 
affinities of labeled and unlabeled IL-1 for the receptor are significantly  different. 
This is crucial in determining whether Bolton-Hunter-labeled IL-1 can be used 
not  only  to  detect  the  receptor  for  the  unmodified  hormone,  but  also  to 
characterize those receptors. If the binding constants of the labeled and unlabeled 
hormone preparations are the same, then affinities, rate constants, and cooper- 
ative  properties  evaluated  with  the  iodinated reagent  may be  taken  as  good 
estimates for the behavior of the unmodified form of the molecule. 
Analysis of the  data  with a  single-site competitive inhibition equation  (23), 
yielded an inhibition constant of 2.4 (_+0.3) x  109/M. The curve passing through 
the  data  was  calculated  with  this  model  (using  this  value  of the  inhibition 
constant). The good fit between theory and experiment is consistent with the 508  CELL  SURFACE  INTERLEUKIN  1  RECEPTORS 
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FIGURE  5.  Inhibition of the binding of 1~sI-IL-1  by unlabeled IL-1. LBRM-33-1A5 cells (1.1 
x  108 cells ml) were incubated with 2.73 x  10 -~° M J251-1L-1, in the presence of unlabeled IL- 
l, at a series of concentrations, for 4 h at 8°C. The continuous curve passing through the data 
was calculated from a  one-site competitive incubation equation  using a Ka value for 1~sI-IL-1 
of 1.90 X  109/M, derived from the data in Fig. 4, and the best-fit Ki value for unlabeled 1L-1 
(given  ill  the text).  Tbe best-fit value  for maxinlum  inhibition was  102  4- 2%.  All data are 
corrected for nonspecific binding measured in the presence of 1.57 x  10  -~ M unlabeled IL-I; 
this value was 1 1 molecules/cell or 4 x  10 l° molecules/(cell. M). In the absence of competitor, 
the cells bound 39 +  1 molecules/cell of 1251-1L-1. 
presence of a  single  class of noncooperative  IL-1  receptors on  LBRM-33-1A5 
cells. In similar experiments with other preparations ofIL-1, purified as described 
by Kronheim  et al.  (10),  we have observed inhibition  constants as high  as 2  x 
101°/M.  The  variation  in  binding activity may be due to variable denaturation 
or  inactivation  of the  IL-1  during  purification,  or  difficulties  in  estimating 
concentrations of protein preparations at the level of 1-10 ~g/ml. This may also 
account for the higher affinity measured by the association kinetics experiment 
shown  in  Fig.  2.  Nevertheless,  a  comparison  between the affinities of the  125I- 
labeled IL-I  used in the experiment shown in Fig. 4 and the unlabeled IL-1 (Fig. 
5), both from the same IL-1 preparation,  indicates that radiolabeling at the level 
of 2-5 x  1015 cpm/mmol produces little loss in affinity for the receptor. 
Fig.  6  illustrates  an  experiment  testing  the specificity of the  LBRM-33-1A5 
IL-1  receptor.  Of a  set  of 12  polypeptide  hormones,  only  IL-1  inhibited  the 
binding  of ~25I-IL-1 to  LBRM-33-1A5 cells at  8°C.  This  suggests, at  least  for 
tnurine T  cells, that the receptor to which IL-1 binds is specific for this polypep- 
tide hormone. 
Affinity Crosslinking  of 125I-IL-1 to LBRM-33-1A5 Cells.  Fig.  7 shows an SDS- 
PAGE analysis of detergent lysates from LBRM-33-1 A5 cells that were incubated 
with 1251-IL-1 in the presence or absence of unlabeled IL-1, washed, and exposed 
to bivalent lysine-directed cross]inking agents. All three of the crosslinkers, DSS, 
DSP, DST, produced a radiolabeled band at ~ 100,000 Mr when the cell lysates 
were analyzed under nonreducing conditions (Fig.  7A).  The crosslinking of IL- 
l  to  the  higher  molecular  weight  species  was  specific,  since  unlabeled  IL-1 
abolished  the  presence  of the  bands  on  the  gel  (Fig.  7,  lanes  2,  4,  6,  and  8). 
Further,  in  the  absence  of crosslinking  agents,  no  cell-associated  radiolabeled DOWER  ET  AL.  509 
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FIGURE 6.  Specificity of the murme T  cell IL-1  receptor.  LBRM-33-1A5 cells (3.4  x  107 
cells/ml) were incubated with 3.50  x  10  -1°  M  12~I-IL-1 alone (A) or with various unlabeled 
hormone preparations: (B) unlabeled IL-1,  1.94 x  10  -s M; (C) thyroid-stimulating hormone, 
3 #g/ml; (D) platelet-derived growth factor, 3 •g/ml;  (E) epidermal growth factor, 3 #g/ml; 
(F) human luteinising hormone, 3 #g/ml; (G) human growth hormone,  1.67 x  10  -7 M; (H) 
insulin  (bovine),  5.6  x  10  -7  M;  (I)  nerve  growth  factor,  3  ~tg/ml;  (J)  follicle-stimulating 
hormone, 3 #g/ml; (K) human IL-2,  2.4 ×  10  -7 M; (L) murine CSF-2a,  2.7  x  10  -9 M; (M) 
bovine pituitary fibroblast growth factor, 3/~g/ml. Some hormone preparations were partially 
pure  and  their  concentrations  are  given  in  ~g/ml  total  protein.  Concentrations of  pure 
hormones are given in molarity. All incubations were done at 8°C for 2 h. 
species was detected other than  IL-1  (lanes  1 and 2).  The uncrosslinked IL-1 
runs at the bottom of the 8% gel; however, in other experiments using 12% gels, 
the Mr of cell-bound IL-1  was  ~17,500, as expected (Fig.  1).  Labeled material 
was  also  detected  at  the  top  of the  running gel,  suggesting the  presence  of 
aggregated protein too large to migrate into the gel. This seemed to be a function 
of the  crosslinker  used,  since  less of the  high molecular weight material was 
observed with  DST  than  with  DSS  or  DSP.  There was a  faint band in  some 
samples, migrating with an Mr of 66,000 (e.g., Fig. 7 B, lane I). We attribute this 
to a low level of contamination of the ~25I-IL-1 preparation with a25I-BSA, since 
SDS-PAGE analyses of some of our unlabeled IL-1  preparations revealed the 
presence of a faint band in this position. 
Lysates of cells treated with a25I-IL-1 and these crosslinkers were also analyzed 
under reducing conditions (Fig.  7B).  As expected, no bands other than  IL-1 
were observed in the reduced samples when the IL-1  had been crosslinked to 
the cells with the cleavable reagent DSP (Fig. 7B, lanes 5 and 6). However, use 
of the crosslinkers DSS and DST resulted in the detection of two bands in the 
gel:  a  major band  of Mr  97,000  and  a  higher  molecular weight  band  of Mr 
133,000.  The M,  97,000  band  was  detected  under  all  conditions examined, 
including when a mixture of protease inhibitors was used during the extraction 
step. It was also present with the lowest concentration of crosslinker (0.1  mg/ml) 
and the shortest incubation time (15 rain) with crosslinker (data not shown). The 
appearance of the M,. 133,000 band, on the other hand, was variable. Its intensity, 
relative to the M, 97,000 band, seemed to be a function of the crosslinker, since 
DSS gave a detectable band at this Mr,  while DST yielded a very faint band at 510  CELL SURFACE INTERLEUKIN  1 RECEPTORS 
FIGURE 7.  Characterization of the  murine T  cell IL-1 receptor  by affinity crosslinking. 
7  10  LBRM-33-1A5 cells (6.7 x  10/ml) were incubated with 5.5 x  10-  M 12~I-IL-1  at 8°C for 2 
h. Negative controls (lanes 2, 4, 6, and 8) contained 1.8 x  10  -8 M unlabeled IL-1. Cells were 
then washed, treated with crosslinker, extracted, and analyzed by SDS-PAGE  as described in 
Materials and  Methods. (A)  Samples were denatured  in  the  absence of mercaptoethanol 
(nonreducing). (B) Samples were denatured  in the presence of mercaptoethanol (reducing). 
(Lanes 1 and 2) Cells were not treated with crosslinker; (lanes 3 and 4) cells were treated with 
1 mg/ml of DSS; (lanes 5 and 6) cells were treated with 1 mg/ml of DSP; (lanes 7 and 8) cells 
were treated with 1 mg/ml of DST. 
this position. The intensity of the Mr  133,000 band appeared to correlate with 
the intensity of the material that failed to enter into the nonreducing gel depicted 
in Fig.  7A. We have focussed on the Mr 97,000 band because it appeared under 
all  crosslinking conditions and  in  each  experiment.  It represents  125I-IL-1  (Mr 
17,500) linked to a plasma membrane protein of Mr 79,500. 
Cellular  Distribution  of IL-I  Receptors.  Table  I  summarizes  the  results  of a 
survey of a number of cell types, primary cells, and established cell lines, for the 
presence of IL-1 receptors. For some cells (Table I, footnote {), complete binding 
curves were done over a range of 1251-IL-1 concentrations and receptor numbers 
per cell were generated by an analysis of the kind used for Fig. 4.  In most cases, 
however, for a  preliminary survey, a  single concentration of 125I-IL-1  was used, 
to determine whether IL-1 receptors were present and their approximate abun- 
dance. 
With  one exception,  the  level  of expression  on primary cells was low (Table 
I).  The  exception,  human  fibroblasts,  expressed  4.9  x  l0 s  receptors  per  cell, 
which  is  to  some  extent  reflected  in  the  generally  higher  levels  of receptor 
expression  on the in  vitro fibroblast lines  in  Table  I. Among a  series of mouse 
lymphoid tissues tested, only PNA- thymocytes showed detectable levels of IL-1 
receptors;  this  is  striking  since  these  murine  lymphocytes are  IL-1  responsive 
(14). DOWER  ET  AL. 
TABLE  I 
Cellular Distribution of lL-I Receptors 
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Species  Cell type 
Primary cells  Molecules bound 
IL-I* 
per cell 
M 
Mouse  Thymocytes  4  ×  10  -l°  <10 
Mouse  Thymocytes PNA  + fraction  4  ×  10  -~°  <10 
Mouse  Thymocytes PNA- fraction  4  x  10  -1°  27 _  5 
Mouse  Spleen cells  4  ×  10  -l°  <10 
Mouse  Lymph node cells  4  x  10  -~°  <10 
Human  Peripheral blood mononuclear cells  4  ×  10  -~°  27 -  1 
Human  T  cell line  4  x  10  -l°  100 +  0 
Human  Gingival fibroblasts  --  4.9 ×  103. 
In vitro cell lines 
Species  Cell type  Designation 
Mouse  T  lymphoma  LBRM-33-1A4  --  550 _  570* 
Mouse  T  lymphoma  LBRM-33-5A4  4  ×  10  -l°  <10 
Mouse  T  lymphoma  EL-4  5  x  10  -l°  185 _  81 
Mouse  Fibroblast  L929  10  -9  144 +_ 28 
Mouse  Fibroblast  SC-1  5  ×  10  -'°  1850 -  112 
Human  T  lymphoma  Jurkat-FHCRC  4  ×  10  -~°  <10 
Human  T  lymphoma  HSB-2  4  ×  10  -~°  79 +  5 
Human  T  leukemia  PEER  5  ×  10  -~°  <10 
Human  Monocyte  U937  4  ×  10  -l°  <10 
Human  Myelogenous leukemia  KG-1  4  ×  10  -~°  <10 
Human  Erythroleukemia  K562  4  ×  10  -~°  <10 
Human  Promyelocyte  HL-60  4  X  10  -L°  <10 
Human  Myeloma  ARH77  5  x  10  -~°  330 ___ 3 
Human  B lymphoma  BMB  5  ×  10  -'°  540 _  0 
Human  Melanoma  A375  --  465 -+ 25* 
Human  Hepatoma  SKHEP-2  5  ×  10  -~°  <10 
Rat  Fibroblast  XC  5  X  10  -~°  450 -  22 
Rat  Hepatoma  HEP-2  --  540* 
Rat  Epithelial cell  HTC  --  510* 
Bovine  Endothelial cell  CPAE  --  750* 
* Concentration of ~sI-IL-1  used to test for the presence of receptors. All data are corrected for 
nonspecific binding of  radiolabeled ligand measured  in  the  presence  of  at  least  1  ×  10  -8  M 
unlabeled IL-1. 
* Binding was tested with a  complete lzsI-IL-1 dose response curve. 
Among the cell lines tested, in addition to fibroblasts, we found that epithelial, 
and  endothelial  cells also showed relatively high  levels of IL-1  binding.  T  cell 
lines showed variable expression and two B cell lines both had significant levels 
of IL-1 receptors. The data clearly show that none of the cells have more than a 
few thousand IL-1 receptors per cell. 
Discussion 
The  distribution  of  IL-1  receptors  among  the  various  cell  types  broadly 
matches the previously reported pattern of cellular IE-1 responsiveness (7, 9,  11, 
12,  14, 32, 34). This is consistent with the hypothesis that the biological effects 512  CELL  SURFACE  1NTERLEUKIN  1  RECEPTORS 
of IL-1  are  mediated  by the  plasma  membrane  receptor(s)  identified  in  these 
studies. 
The level of expression of IL-l-binding sites was low, compared, for example, 
with receptor levels for IL-2 on T  cells (33).  Our results suggest that  IL-1  can 
exert its biological  effects at  levels of 1-100  molecules bound per cell.  In  the 
case of thymocytes and LBRM-33-1A5 cells, this may not be surprising, since IL- 
l  acts by inducing  IL-2 production  (12,  14),  which  can  presumably provide a 
large degree of signal amplification. Conversely, where IL-1 is directly mitogenic 
(for example, on fibroblasts; 9, 34), the levels of receptor expression seem to be 
somewhat higher.  Further, the levels of receptor expression on thymocytes seem 
to be one to two orders of magnitude  less than  on  LBRM-33-1A5 cells.  This 
correlates with  the lower specific activity of purified  IL-1  in  the thymocyte co- 
mitogenesis  assay (4.4  X  10 7  U/mg)  when  compared  with  the LBRM-33-1A5 
conversion assay (5.7 X 10 j° U/mg). This suggests that a minimum absolute level 
of IL-1/IL-1  receptor complexes may be needed  to  deliver a  signal  to a  cell, 
which  may  be  achieved  by  increasing  either  IL-1  concentration  or  receptor 
number,  as has been suggested for IL-2 (35).  It may be,  however, that  only a 
minority  of the  PNA- thymocytes express IL-1  receptors and,  hence,  produce 
IL-2  in  response  to  IL-1,  while  presumably  LBRM-33-1A5  all  bear  receptors 
since they are of clonal origin. 
The  specific activity of IL-1  when  assayed on  LBRM-33-1A5  cells suggests 
that  ~10 -14 M IL-1  is sufficient to induce 50% maximal  response from LBRM- 
33-1A5 cells at  37°C over 24 h.  The  binding  studies show that  the affinity of 
unmodified IL-I  for LBRM-33-1A5 cells is 109 to 10~°/M; hence the concentra- 
tion  of IL-1  required  to produce 50%  maximal  receptor occupancy is  10 -9 to 
10 -J°  M.  These  concentrations  are  apwoximately  four  orders  of magnitude 
higher  than  those required  to produce the biological effects. The  kinetic  data 
show that the equilibrium binding studies closely reflect the true receptor affinity, 
since the measured reverse rate constant of 2 x  10-2/min gives a maximum half- 
time of ~30-50 min for binding of IL-1  to LBRM-33-1A5 cells, and the assays 
were done  for 4  h.  However, we observed a  slowly exchanging  component  in 
the dissociation kinetics experiments, and it may be that this reflects a subpopu- 
lation  of receptors  capable  of effectively and  irreversibly  binding  IL-1.  This 
interaction  may  be primarily  responsible  for  the  capacity of IL-1  to  produce 
biological effects at such low concentrations on cells with low levels of receptor 
expression. We have only studied in detail the binding of IL-1 to the LBRM-33- 
1A5  cell  line;  whether  these  observations  can  be  generalized  to  other  IL-1- 
responsive cells remains to be investigated. 
The crosslinking experiments provided some preliminary  structural  informa- 
tion on the murine T  cell IL-1  receptor protein.  The most likely candidate for 
the  IL-l-binding  protein  is the one with  an  Mr of 79,500.  This protein,  when 
crosslinked to  1z5I-IL-1,  resulted in an M,. 97,000  band on polyacrylamide gels 
under reducing conditions.  It migrated on nonreducing gels at a similar molec- 
ular weight, suggesting that the binding protein is not covalently linked to other 
subunits as  part  of a  receptor  complex.  The Mr  97,000  protein  was detected 
under all  conditions.  It appeared within  minutes of the addition  of crosslinker 
to cells, and was present as the only detectable band when cells were lysed in the DOWER  ET  AL.  513 
presence of a mixture of protease inhibitors. It is therefore unlikely to be related 
to the M, 133,000 band as a result of either proteolysis or aggregate formation 
of the M,. 97,000 protein  due to extensive crosslinking.  The Mr  133,000 band 
was most intense  in  samples from cells that  had  been  crosslinked with  DSS, a 
more hydrophobic reagent  than  the crosslinker  DST.  DSS may partition  more 
effectively into the plasma membrane, and crosslink the 125I-IL-1/IL-1 receptor 
complex to a second, closely associated membrane protein of Mr 36,000. Alter- 
natively, ~25I-IL-1, in the presence of DSS, could be crosslinked to an Mr 115,500 
protein closely associated with the Mr 79,500 protein on the plasma membrane. 
These  suggestions  are  speculative.  The  data  do  not  allow  a  definite  choice 
between the models. 
The receptor protein we have identified and characterized in these studies was 
detected using IL-1  purified to homogeneity from activated human  monocytes 
(10). We and others (36, 37) have recently cloned the gene encoding this protein 
(IL-1/3).  A  second  form  of human  IL-1  (IL-lct)  has  been  identified  in  our 
laboratory using a  recombinant  DNA approach  (36).  Preliminary  data suggest 
that  IL-I~ and  IL-ll3 both bind to the Mr 79,500  receptor protein on LBRM- 
33-1A5 cells. 
Finally, the availability of an assay for the presence of IL-1 receptors makes it 
possible to screen for monoclonal antibodies directed against this protein, and to 
search for cell lines expressing high  levels of receptor.  These will be important 
steps towards isolating and characterizing the receptor protein(s) and the gene(s) 
that encode it. 
Summary 
Interleukin  1 (IL-1) is a polypeptide hormone  that acts as a  central  mediator 
ofinfiammation. Since IL-1 action is presumably mediated by specific cell surface 
receptor(s), we have characterized the binding of this hormone to cells. Purified 
human  IL-1  was labeled to high  specific activity with  125I, using Bolton-Hunter 
reagent.  The  labeled protein  binds specifically to  LBRM-33-1A5 (a murine  T 
lymphoma line previously shown to produce IL-2 in response to phytohemagglu- 
tinin and IL-1) with an affinity of ~0.2-2  X  101°/M and, at saturation,  to ~500 
receptors per cell, on intact cells at  8°C in the presence of sodium azide.  The 
affinity of unmodified IL-1 for the murine plasma membrane receptor is 0.9-2 
x  101°/M,  as  measured  by  the  inhibition  of  125I-IL-1 binding,  The  murine 
receptor specificity has been confirmed by demonstrating  that,  among a  series 
of 12 polypeptide hormones,  only IL-1  inhibits  125I-IL-1 binding to LBRM-33- 
1A5  cells.  Treatment  of surface-bound  ~25I-IL-1 with  bivalent  water-soluble 
crosslinkers identified  a  membrane  polypeptide of Mr 79,500  to which  IL-1  is 
crosslinked. 
A  variety of cell types have been surveyed for the capacity to bind  ~25I-IL-1 
specifically. The presence of specific binding correlates with the capacity of the 
cells tested to respond to IL-1. Our results indicate that the biological effects of 
the polypeptide hormone  I L-1  are mediated by high affinity plasma membrane 
receptors. The identification  of these receptors should provide valuable insight 
into the apparently diverse biological activities of IL-1. 514  CELL  SURFACE INTERLEUKIN  1  RECEPTORS 
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